GREENLAND MINES LTD Other Research and Development Expense
GREENLAND MINES LTD (GRML) reported Other Research and Development Expense of $400.54 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherResearchAndDevelopmentExpense · last filed 2026-08-17
- GREENLAND MINES LTD other research and development expense for the quarter ending 2026-06-30 was $400.54K, a 67.80% increase year-over-year.
- GREENLAND MINES LTD other research and development expense for the quarter ending 2025-06-30 was $238.70K.
| Period end | Other Research and Development Expense 3 month | Other Research and Development Expense 6 month |
|---|---|---|
| 2026-06-30 | $400.54K 10-Q · filed 2026-08-17 | $721.81K 10-Q · filed 2026-08-17 |
| 2025-06-30 | $238.70K 10-Q · filed 2026-08-17 | $238.70K 10-Q · filed 2026-08-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |